Sanofi: Hypertension trials
The registry lists 29 Hypertension studies with Sanofi as lead sponsor. 0 are open to participants now and 0 have results posted.
Phase 2 2Phase 3 7Phase 4 20No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of Efficacy and Safety of Irbesartan/Amlodipine 4 Fixed Combination Therapy in Hypertensive Patients Uncontrolled on Irbesartan or Amlodipine MonotherapyCompletedNCT01625494Phase 3
- Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Irbesartan 150 mg MonotherapyCompletedNCT00957554Phase 3
- Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Amlodipine 5 mg MonotherapyCompletedNCT00956644Phase 3
- Irbesartan and Amlodipine Combination in Controlling Blood PressureCompletedNCT00950066Phase 2
- Irbesartan-Hydrochlorothiazide Phase IV Study: Treatment of Hypertension in Chinese PopulationCompletedNCT00847834Phase 4
- China Medical University Hospital (CMUH) Triapin ListingCompletedNCT00841880Phase 4
- ACTUAL: Efficacy and Safety of Irbesartan/Hydrochlorothiazide CombinationCompletedNCT00708344Phase 4
- Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive PatientsCompletedNCT00670566Phase 4
- Evaluation of Efficacy and Safety of the Dosage Adjustment of Aprovel® (Irbesartan) in Hypertensive Outpatients in Current Clinical PracticeCompletedNCT00564187Phase 4
- The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild HypertensionCompletedNCT00562809Phase 4
- Randomized, Parallel, Comparison, Double-Blind Efficacy & Safety Study of APROVEL Versus Placebo in Chinese Patients With Hypertensive Type II Diabetic Patients With MicroalbuminuriaCompletedNCT00561964Phase 3
- Irbesartan Effects on Endothelial Dysfunction in Hypertensive Type II Diabetic Patients Comparing AtenololCompletedNCT00549133Phase 4
- Effect of the Angiotensin II Receptor Antagonist Irbesartan on Biochemical and Functional Markers of Endothelial Dysfunction in Patients With HypertensionCompletedNCT00529750Phase 4
- Use of Ramipril and Felodipine Combination Therapy in Hypertension: An Effectiveness Study With Local Patients in ArgentinaCompletedNCT00507845Phase 4
- Efficacy of Irbesartan/Hydrochlorothiazide Versus Valsartan/Hydrochlorothiazide in Mild to Moderate HypertensionCompletedNCT00500604Phase 4
- Irbesartan/Hydrochlorothiazide National Taiwan University Hospital ListingCompletedNCT00443612Phase 4
- I PREVENT - Irbesartan In Hypertensive Diabetic PatientsCompletedNCT00362258Phase 4
- I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular HypertrophyCompletedNCT00362037Phase 4
- Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial FunctionsCompletedNCT00350038Phase 4
- I SAVE - Irbesartan in Mild to Moderate Hypertensive PatientsCompletedNCT00335673Phase 4
- Irbesartan in Chinese Hypertensive Diabetics With MicroalbuminuriaCompletedNCT00334581Phase 4
- Ramipril - HypertensionCompletedNCT00325806Phase 4
- ARCHIPELAGO: Irbesartan in Patients With Acute Coronary Syndrome Without ST Segment ElevationCompletedNCT00296218Phase 3
- AVE7688 in Patients With Mild to Moderate Blood PressureCompletedNCT00284128Phase 2/3
- APROVE : Irbesartan in HypertensionCompletedNCT00283036Phase 4
- Irbesartan in HypertensionCompletedNCT00265967Phase 4
- AMISH : Aprovel for Management of Isolated Systolic HypertensionCompletedNCT00264212Phase 4
- Irbesartan/Hydrochlorothiazide and Irbesartan in the Treatment of Mild to Moderate HypertensionCompletedNCT00263003Phase 3
- RIAT Registry: Reason for Not Intensifying Antihypertensive TreatmentCompletedNCT00258921